Insights on Discovery

31. High-Throughput Screen Finds Targets To Boost AAV9 Production In HEK293 Cells 2/5/2025

    Take a look at the potential of this small molecule screening to enhance AAV9 production and improve gene therapy manufacturing efficiency by leveraging novel compounds.

32. Plasmid Impurity Sizing Of nptII In rAAV By ddPCR 2/5/2025

    Explore our novel ddPCR method for assessing plasmid-derived antibiotic resistance gene impurities in rAAV products to enhance regulatory compliance and ensure the safety and quality of gene therapy vectors.

33. Method Qualification Of Mass Photometry For The Determination Of Full-To-Empty Capsid Ratio For rAAVs Using The Refeyn System 2/5/2025

    Leverage mass photometry to quickly and accurately monitor the full-to-empty ratio of rAAV samples, ensuring consistent product quality and enhanced safety and efficacy in gene therapy applications.

34. Design Of Experiment (DoE) Based High Throughput Process Optimization For rAAV Manufacturing Development 2/5/2025

    This study presents the results of a Design of Experiment (DoE) approach to assess how these process parameters impact rAAV yield and quality.

35. Quality Over Quantity: Where Is The Trade Off? 2/5/2025

    Our study aims to compare two widely used transfection reagents to our standard process, evaluating their impact on final product quantity and quality as part of our ongoing platform innovation efforts.

36. New Hope For Neuronal Diseases With Polymer Nanoparticle-Based Gene Therapy 1/28/2025

    A new polymer nanoparticle (PNP) system enables targeted delivery of large genetic payloads to neuronal cells, advancing gene therapies for NF1 and other nervous system disorders.

37. Fit-For-Purpose Biomarker Development 1/17/2025

    Here, we highlight the essential framework of a “fit-for-purpose” biomarker development strategy, emphasizing strategic and transactional engagements with clinical research organizations.

38. Biomarkers In Oncology Studies 1/17/2025

    Here we provide an overview of oncology biomarker development and strategic considerations.

39. LC-MS/MS Method Development Of Endogenous Small Molecule Biomarker 1/17/2025

    Biomarkers are essential to improve drug R&D efficiency. Explore some practical solutions for achieving a fit-for-purpose LC-MS/MS biomarker analysis method.

40. Exploring Progress In Nanomedicine: Unlocking New Possibilities For Treating Rare Genetic Diseases 1/15/2025

    Gene therapy offers hope for rare genetic diseases, with advancements in polymer nanoparticles addressing delivery challenges and paving the way for innovative, effective treatments.